WALTHAM, Mass.--(BUSINESS WIRE)--
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will be presenting at the Spotlight on Dry Eye session at the Ophthalmology Innovation Summit at the American Society of Cataract and Refractive Surgery Annual Meeting (OIS@ASCRS) taking place on April 12, 2018. Data from the Phase 3 clinical trials conducted with INVELTYS™ (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pain following ocular surgery, will also be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting taking place April 13-17, 2018 in Washington, D.C.
Details of the presentations are as follows:
Meeting: OIS@ASCRS
Session title: Spotlight on Dry Eye
Date:
Thursday, April 12, 2018
Time: 10:40 - 11:25 AM
(presentation from 10:45-10:51 AM ET)
Location: The
Renaissance Washington, D.C. Downtown Hotel
Presenter: Mark
Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals
Meeting: ASCRS
Title: Safety and Efficacy of Twice
Daily Administration of KPI-121 1% for Ocular Inflammation and Pain
Following Cataract Surgery
Date: Monday, April 16, 2018
Time:
2:01 - 2:06 PM ET
Location: Walter E. Washington Convention
Center, 143B
Presenter: Terry Kim, M.D., Professor of
Ophthalmology, Duke University School of Medicine; Chief, Cornea and
External Disease Division; Director, Refractive Surgery Service, Duke
University Eye Center
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180409005434/en/
